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Non-clinical development of CER-001
Ronald Barbaras*
Cerenis Therapeutics, Labege, France
Cardiovascular disease remains the most pressing healthcare issue for the developed
world and is becoming so for developing countries. There are no currently approved
therapies that can rapidly reduce the burden of unstable, inflamed plaque in the overall
coronary vascular bed. High-density lipoprotein (HDL) has multiple actions that could
lead to plaque stabilization, such as rapid removal of large quantities of cholesterol
from the vasculature through the process of reverse lipid transport, improvement in
endothelial function, protection against oxidative damage, and reduction in inflammation.
Short-term infusion of HDL-mimetics in animal models as well as in humans has
shown promising effects on the plaque size and morphology. Cerenis Therapeutics has
developedCER-001, a negatively charged lipoprotein complex consisting of phospholipid
and recombinant human apoA-I that mimics the structure and function of natural HDL.
Three clinical trials using CER-001 infusions have demonstrated improvements in the
carotid wall thickness of patients with familial hypercholesterolaemia and in patients with
hypo-alphalipoproteinaemia, as well as an impact on coronary plaque burden measured
by intravascular ultrasonography at the lowest tested dose (3 mg/kg) in post-ACS
patients. Here, we reviewed the non-clinical data leading to the demonstration that
CER-001 is a full HDL mimetic.
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Introduction
Cardiovascular disease remains the most pressing healthcare issue for the developed world and is
becoming so for developing countries. A number of chronic therapies are available for long-term
management of risk. Short-term therapeutic interventions in subjects with an acute event, such
as an episode of acute coronary syndrome (ACS; myocardial infarction or unstable angina), are
centered around attempts at reperfusion of the affected myocardium and reduction of thrombus
(Piccolo et al., 2015); however, most subsequent events are caused by plaque rupture at a
different site. Long-term treatment focuses on reducing cardiovascular risk on top of conventional
therapies such as antithrombotic agents, beta-blockers, therapies addressing risk factors, etc,
by lowering low-density lipoprotein cholesterol (LDL-C; Hirsh et al., 2015). This strategy has
resulted in an impressive reduction in recurrent events of about one third, but still leaves a
residual risk (the remaining two thirds of events) unaddressed. There are no currently approved
therapies that can rapidly reduce the burden of unstable, inflamed plaque in the overall coronary
vascular bed. High-density lipoprotein (HDL) has multiple actions that could lead to plaque
stabilization, such as rapid removal of large quantities of cholesterol from the vasculature through
the process of reverse lipid transport (RLT), improvement in endothelial function, protection
against oxidative damage and reduction in inflammation. In the first randomized trial of HDL
infusion in humans, the intravenous administration of recombinant apolipoprotein (apo) A-IMilano
(a naturally occurring variant of human apoA-I with Arg-173 to Cys substitution) in a complex with
phospholipid (ETC-216) produced a significant reduction in coronary atherosclerosis as measured
Frontiers in Pharmacology | www.frontiersin.org October 2015 | Volume 6 | Article 2201
Barbaras CER-001, a pre-beta HDL mimetic
by intravascular ultrasonography (IVUS; Nissen et al., 2003).
Another study, using purified apoA-I from human plasma
combined with soybean phosphatidylcholine (CSL-111), resulted
in significant improvements in the plaque characterization index
and coronary score on quantitative coronary angiography in
humans (Tardif et al., 2007). This observation, was further
confirmed on a trial where atherectomy to excise plaque was
performed on superficial femoral artery of patients (n = 10)
with claudication. After one infusion at 80 mg/kg significant
improvement of the lipid content, the macrophage size and the
inflammation markers of the plaques were measured (Shaw et al.,
2008).
Cerenis Therapeutics has developed CER-001, a negatively
charged lipoprotein complex consisting of phospholipid
and recombinant human apoA-I that mimics the structure
and function of natural HDL. Three clinical trials using
CER-001 infusions have demonstrated improvements
in the carotid wall thickness of patients with familial
hypercholesterolaemia (Hovingh et al., 2015) and in patients
with hypo-alphalipoproteinaemia (Kootte et al., 2015), as well
as an impact on coronary plaque burden measured by IVUS at
the lowest tested dose (3 mg/kg) in post-ACS patients (Andrews
et al., 2014; Tardif et al., 2014).
The anti-atherosclerotic properties of HDL infusion were
first demonstrated in animals by Badimon et al. (1989) who
reported decreased progression of atherosclerotic lesions with
weekly infusions of aHDL–very high-density lipoprotein (VHDL)
fraction in cholesterol-fed rabbits. Indeed, lipid-rich lesions
covered 37.9  6.0% of the intimal aortic surface in the control
group (normal saline) but only 14.9  2.1% in the treated
group (50 mg/kg of homologous HDL–VHDL protein). Total
cholesterol, unesterified cholesterol, esterified cholesterol and
phospholipids deposited within the vessel wall were significantly
lower in the aortas of the HDL–VHDL-treated group than in the
control group, whereas plasma lipid levels were similar in the two
groups.
The effects of homologous plasma HDL–VHDL infusions
on established atherosclerotic lesions were further evaluated in
a separate study with cholesterol-fed rabbits (Badimon et al.,
1990). Atherosclerosis was induced by feeding the animals a 0.5%
cholesterol-rich diet for 60 days (group 1) or 90 days (group 2), and
thiswas assessed by histological evaluation.A third group received
the same diet plus infusions of 50 mg of HDL–VHDL protein
per week (isolated from normolipaemic rabbit plasma). At the
completion of the study, aortic atherosclerotic involvement and
lipid deposition were significantly reduced in the HDL–VHDL-
treated animals at 90 days as compared with the 90-day controls
(group 2) and the 60-day controls (group 1). This study was the
first in vivo prospective evidence of the anti-atherogenic effect
of HDL–VHDL against pre-existing atherosclerosis, supporting
the hypothesis that HDL administration may not only slow
lesion progression but may also reduce established atherosclerotic
lesions.
The effects of intravenous injection of purified rabbit lipid-free
apoA-I on the progression of aortic atherosclerosis in cholesterol-
fed rabbits were examined byMiyazaki et al. (1995). Firstly, rabbits
were fed a 0.5% cholesterol-rich diet for 90 days. During the
last 30 days, the rabbits in the treatment group received weekly
infusions of 40 mg of apoA-I. At the completion of the study,
the fatty streak lesions in the treated group (23.9  15.6% of
total aorta) were significantly decreased compared with those
in the untreated group (46.0%  24.9%; P < 0.05). In a
second experiment, cholesterol-fed rabbits (105 days of diet) were
maintained for an additional 60 days on a normal diet, during
which they received either apoA-I 1 mg every other day or
apoA-I 40 mg every week. Although this study did not observe
atherosclerosis regression, it did provide the first evidence of the
anti-atherogenic effect of homologous apoA-I on the progression
of atherosclerosis in cholesterol-fed rabbits.
The effect of recombinant apoA-IMilano on intimal thickening
after balloon injury in cholesterol-fed rabbits was reported by
Ameli et al. (1994). Rabbits received intravenous injections of
40 mg of apoA-IMilano as part of a phospholipid complex on
alternate days, beginning 5 days before, and continuing for
5 days after, balloon injury of femoral and iliac arteries. ApoA-
IMilano significantly reduced intimal thickening and macrophage
content further implying the therapeutic potential of such a
treatment strategy. Later studies, using adenovirus coding for
apoA-I, further supported the anti-atherogenic properties of
apoA-I, which associates with phospholipids to form nascent
HDL (Feng et al., 2009). Several groups have demonstrated that
apoA-I complexed with phospholipids behaves like natural HDL
after intravenous administration in humans (Nanjee et al., 1999;
Nieuwdorp et al., 2008; Feng et al., 2009; van Leuven et al., 2009).
High-density lipoprotein comprises particles of various sizes,
depending on the quantity of cholesterol each particle has
mobilized and is carrying for transport to the liver for elimination.
Newly formed HDL particles (also called pre-b HDL) are the
smallest lipid-poor particles; they are essentially “empty” and have
the greatest ability to mobilize cholesterol. A natural pre-bHDL is
a lipoprotein consisting of apoA-I and phospholipids interacting
together to form a small discoidal particle. In a normal individual,
pre-b HDL particles represent only 10% of the total cholesterol
associated with HDL. These small particles increase in size as they
accumulate cholesterol, creating larger, “full,” and mature alpha-
HDL particles capable of delivering the acquired cholesterol to the
liver for elimination.
Preclinical studies have demonstrated that CER-001, a
bioengineered pre-b HDL nanoparticle, has all the biological
properties of natural HDL including the capacity to regress
atherosclerotic plaque. CER-001 affects all steps of the
RLT pathway, as does natural HDL, thus validating the
design, functionality and assembly of the particle during
the manufacturing process.
 In cellular models, CER-001 was shown to be an effective
acceptor of cholesterol.
 In vivo, CER-001 mobilizes cholesterol (in a dose-dependent
manner) as shown by an increase in HDL-C.
 CER-001 stimulates lecithin cholesterol acyltransferase
(LCAT) activity resulting in increased esterification of
cholesterol.
 CER-001 increases elimination of cholesterol in the feces.
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FIGURE 1 | Increase in plasma phospholipid and apoA-I following
infusion of CER-001. CER-001 (20 mg/kg) was infused into fasted rabbits.
There were three animals per group. At various times post dose, plasma
phospholipid and apoA-I levels were measured. Plasma human apoA-I levels
were measured by a human apoAI-specific enzyme-linked immunosorbent
assay (ELISA). Baseline values 1.17 g/l were subtracted to determine the
increase in plasma phospholipid levels. The values had returned to baseline
levels by 30–34 h post dose.
 Finally, CER-001 specifically mimics the behavior of a natural
pre-b HDL as shown by the similar dose-dependency of
atherosclerosis regression for CER-001 and a natural pre-b
HDL.
Among the different HDL properties, the capacity to remove
cholesterol from cholesterol-loaded macrophages present in the
atherosclerotic plaques could be a pre-requisite for defining
functional HDL particles.
CER-001 Composition; Effect of the Charge
The phospholipid species used in CER-001 were selected for
their ability to form a discoidal complex with a strong affinity
for cholesterol (Mattjus and Slotte, 1996; Ramstedt and Slotte,
1999), a negative charge to slow clearance by the kidney (Guasch
et al., 1993), their ability to trigger recognition by the liver
(Guasch et al., 1993; Rigotti et al., 1995) and also for the high
stability of the complexes in the circulation (Figure 1; Baron
et al., 2010). Early studies focused on optimizing the composition
to produce a homogeneous population of stable protein/lipid
complexes that eluted in the same fraction as natural pre-b
HDL in column chromatography (size) and migrated similarly to
natural HDL in gel electrophoresis (charge; Tardy et al., 2015).
The formulation for CER-001 consists of a recombinant human
apoA-I produced by genetically modified Chinese hamster ovary
(CHO) cells and a protein-to-lipid weight ratio of 1:2.7. The
phospholipid component consists of natural egg sphingomyelin
and dipalmitoylphosphatidylglycerol in a 97:3 weight ratio (Tardy
et al., 2015).
CER-001 and Cholesterol Efflux
Determination of cholesterol efflux from macrophages is
considered the hallmark of HDL activity/capacity for recycling
cholesterol from cells (Khera et al., 2011). Cholesterol is a
membrane constituent that maintains structural domains
important in the regulation of vesicular trafficking and signal
transduction. In most cells, cholesterol is not catabolized.
Thus, the regulation of cellular sterol efflux plays a crucial
role in cellular sterol homeostasis. Cellular sterol can efflux to
extracellular sterol acceptors by non-regulated, passive diffusion
mechanisms as well as by an active, regulated, energy-dependent
process mediated by the adenosine triphosphate-binding
cassette (ABC) A1 (ABCA1) transporter and, to a lesser extent,
the ABCG1 transporter. The ABCA1 transporter mediates
the cellular efflux of lipids, in particular phospholipids and
cholesterol, from peripheral tissues to lipid-poor apoA-I in the
plasma to form pre-b HDL particles. In preclinical models, the
role of both hepatic and extrahepatic ABCA1 in the assembly
of the HDL particle has been demonstrated. In humans,
homozygous mutations in the ABCA1 gene leading to defective
or non-functional ABCA1 receptors result in Tangier disease,
characterized by profoundly decreased HDL-C, apoA-I and
apoA-II levels, reduced total cholesterol, LDL-C, and apoB,
elevated plasma triglyceride levels leading to an increase in
cardio-vascular disease. With ABCA1 deficiency, apoA-I is
rapidly cleared before it is able to acquire cholesterol; therefore,
the cholesterol storage disorder that occurs with ABCA1
mutations may be more a consequence of HDL deficiency than
a direct consequence of dysfunctional ABCA1 (Attie et al.,
2001).
It was previously shown that CER-001 stimulated the
cholesterol efflux from mouse macrophages in a similar way
to HDL3. This similarity was also noted when evaluated in
human macrophages (THP-1), demonstrating CER-001 to
be a functional HDL particle that captures cholesterol from
macrophages in different species (Tardy et al., 2014). The
CER-001-mediated cholesterol efflux increased in a dose-related
manner with concentrations of the complex and was similar to
the HDL3-mediated cholesterol efflux. The HDL3 cholesterol
efflux determined in the experiment is similar to previous
reports in the literature (Cogny et al., 1996; Bortnick et al.,
2000; Suc et al., 2003). CER-001 is fourfold more potent than
lipid-free apoA-I in effluxing cholesterol from macrophages.
In these defined experimental conditions, cholesterol efflux
from J774 macrophages reached a plateau at 100 mg/ml of
CER-001 (Tardy et al., 2014). These data suggest that the observed
cholesterol efflux was specific for the acceptor added on the
cells.
Up-regulation of ABCA1 expression by cyclic adenosine
monophosphate (cAMP) increases the cholesterol efflux in
macrophages (named ABCA1-specific efflux; Oram et al., 2000).
Under these conditions, a high lipid-free apoA-I cholesterol
efflux was observed as described previously (Oram et al., 2000).
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This lipid-free apoA-I efflux is higher than CER-001 and HDL3
cholesterol efflux (Tardy et al., 2015). The number of cholesterol
acceptors (i.e., the HDL3, CER-001 and delipidated apoA-I) in
the culture medium of the cell (25 mg/ml) is high enough to
accommodate all the cellular cholesterol and so is not a limiting
factor that could explain this observation. One hypothesis is that
a down-regulation of the ABCA1 by HDL3 and CER-001 would
impair the cholesterol efflux capacity of the macrophages. Thus,
an ABCA1 mRNA down-regulation induced by CER-001 and
HDL3 could be associated with a reduction in the ABCA1-specific
cholesterol efflux from macrophages. Indeed, it was observed
that at CER-001 or HDL3 concentrations >20 mg/ml, ABCA1
mRNA expression decreases to half that of control values in J774
macrophages. Delipidated apoA-I did not change the ABCA1
mRNA level even at concentrations up to 300 mg/ml (Tardy et al.,
2015).
ABCA1 protein content was measured in macrophages treated
with CER-001, HDL3, or apoA-I (Oram et al., 2000). As
expected, the addition of cAMP boosted the ABCA1 protein
level compared with untreated macrophages. In the presence
of a high dose (250 mg/ml) of CER-001 or HDL3, the ABCA1
protein level in the membrane was halved. Delipidated apoA-I
did not affect macrophage ABCA1 protein content (Tardy et al.,
2015).
In summary, ABCA1 mRNA and protein level are decreased
after high dose treatment with CER-001 or HDL3. Further
analysis is needed, but one can hypothesize that the down-
regulation of ABCA1 could occur when a low level of cholesterol
is reached in the macrophages. Indeed, cholesterol efflux from
macrophages measured in the presence of b-cyclodextrin
also down-regulates ABCA1 expression. b-cyclodextrin is
a well-known potent acceptor of cholesterol, independent
of any cellular transporters and/or receptors (Field et al.,
2008).
CER-001 and In Vitro Inflammation
Chronic inflammation is considered another hallmark of the
development and progression of the atherosclerotic plaque
(Ross, 1999). Lipopolysaccharide (LPS) and tumor necrosis
factor-a (TNF-a) are implicated in the induction of cytokines and
adhesion molecule secretion. These mediators are responsible
for increasing monocyte infiltration into the arterial wall,
promoting the development of atherosclerotic plaques. To
test whether CER-001 regulated the expression of LPS- or
TNF-a-induced inflammatory molecules such as interleukin
IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1)
and granulocyte-macrophage colony-stimulating factor (GM-
CSF), the media of human umbilical vein endothelial cells
(HUVEC) exposed to LPS in the absence or presence of CER-
001, HDL2, HDL3 or lipid-free apoA-I, was collected (Tardy
et al., 2014). Increasing concentrations of CER-001 reduced the
secretion of all the cytokines tested in a dose-dependent manner
starting at 5 mg/ml, with complete inhibition at 500 mg/ml.
Treatment with purified HDL2 and HDL3 lipoproteins, and
lipid-free apoA-I (500 mg/ml) had a modest effect on cytokine
secretions. When LPS was added to HUVEC, the cells secreted
inflammatory molecules, which in turn were able to recruit
non-adherent monocytes. In the presence of LPS, a dose-
dependent decrease in THP1 monocyte recruitment was
observed when CER-001 was added, with a significant decrease
starting at 5 mg/ml. This observation was further confirmed
by using TNF-a as an alternative inducer of the inflammatory
mediators.
CER-001 and Cholesterol Mobilization In
Vivo
When CER-001 was infused into rabbits at doses ranging
from 2.5 to 20 mg/kg, a dose-dependent increase in plasma
phospholipids and human apoA-I was observed, reflecting the
infusion of the apoA-I and phospholipid content of CER-001.
The prolonged residence of apoA-I in the HDL fraction suggests
that CER-001 is stable throughout the cholesterol mobilization
process (Figure 3C). Dose-dependent cholesterol mobilization
was evident by the increase in plasma unesterified cholesterol as
well as esterified cholesterol (Figure 2). The increase of esterified
cholesterol could be the consequence of LCAT activity, the
enzyme responsible for the cholesterol esterification in plasma.
HDL-C (unesterified and esterified cholesterol) increased at doses
of 5 mg/kg and greater, with peak increases in HDL total
cholesterol occurring 30 min after initiation of the CER-001
infusion (Figure 3). The plasma phospholipid and cholesterol
values returned to baseline levels by 30 to 34 h post dose (Baron
et al., 2010).
The cholesterol mobilization profile following a single dose
of CER-001 (10 mg/kg) in C57Bl/6J mice was similar to that
observed in rabbits. Following injection, the human apoA-I
reached maximal concentration of over 300 mg/ml in 15 min
in the mouse plasma. After 4 h, half of the injected complex
had been eliminated, and 15% of human apoA-I was detected
in the plasma of the injected mice. The plasma total cholesterol
curve after single-dose CER-001 treatment paralleled the apoA-I
pharmacokinetic curve (i.e., they were superimposable), reaching
amaximum at about 30min. Again, half of this pool of cholesterol
was cleared from plasma in the next 4 h. As expected, most of the
plasma cholesterol mobilized was unesterified cholesterol (Tardy
et al., 2014).
CER-001 Increases Plasma Cholesterol
Clearance of LDLr /  Mice
Reverse lipid transport is the process by which excess cellular
cholesterol is liberated from peripheral tissues by HDL and
delivered to the liver for elimination via the intestine (Lewis and
Rader, 2005). LDL receptor knockout (LDLr / ) mice (an animal
model of familial hypercholesterolaemia) were fed with a high fat
diet (HFD) for 10–11 weeks to develop atherosclerotic lesions.
After this time, CER-001 (10 mg/kg) was given intravenously
every second day starting either at week 8 (10 doses) or at week 9
(5 doses). The lipid analysis of the livers showed that unesterified
cholesterol and cholesterol ester concentrations were increased
by 10% in the livers of mice injected with CER-001 (compared
with control mice). In addition, the cholesterol excretion in feces
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FIGURE 2 | Increase in plasma HDL (A) total cholesterol and HDL (B) unesterified cholesterol following infusion of CER-001. CER-001 was infused into
fasted rabbits at doses of: 0 (squares), 2.5 (triangles), 5 (inverted triangles), 10 (diamonds), or 20 (circles) mg/kg. There were three animals per group. At various times
post dose, plasma HDL total and unesterified cholesterol were measured. Baseline values were subtracted to determine the increase in plasma HDL cholesterol
levels. Baseline HDL total and unesterified cholesterol ranged from 0.19 to 0.45 g/l for total and from 0.06 to 0.13 g/l for unesterified cholesterol. By 30–34 h post
dose the values had returned to a value at or below baseline. (C) ApoA-I HPLC gel permeation chromatography profile. This is an example of an elution profile for
human apoA-I at 2 h (dashed line) and 4 h (plain line) after infusion of CER-001 (20 mg/kg). Light dashed lines correspond to total cholesterol profile at 4 h. The
elution times of 30 to 40 min correspond to the HDL fraction, while 18–22 min and 25–30 min correspond to VLDL and LDL, respectively.
was also increased (by 27%) in mice treated with CER-001 at a
dose of 10 mg/kg. In conclusion, infusion of CER-001 increased
cholesterol clearance by the liver into the feces primarily in the
form of unesterified cholesterol, thus demonstrating that CER-
001 performed the final step of RLT in these mice (Tardy et al.,
2014).
CER-001 Inhibits Plaque Progression and
Plaque Inflammation in LDLr /  Mice
LDLr /  mice, following 10–11 weeks on a HFD, developed
atherosclerotic lesions in the aortic root, characterized by fatty
streaks and accumulation of macrophage foam cells (Tardy et al.,
2014). CER-001 (10 mg/kg) given intravenously every second
day starting at either week 8 (10 doses) or at week 9 (5 doses)
reduced plaque size by 17% (5 doses) and 32% (10 doses), and
lipid content by 17% (5 doses) and 23% (10 doses), respectively.
Plaque inflammation was also reduced; there was an 80% decrease
of lesionmacrophage content (5 doses), and vascular cell adhesion
molecule-1 (VCAM-1) expression decreased by 16% (5 doses) and
22% (10 doses). These data demonstrate that infusion of CER-
001 in LDLr /  mice slowed the formation of atherosclerotic
plaques and reduced the associated inflammation after short-term
multiple-dose treatment of CER-001 (Tardy et al., 2014).
Attenuated Inhibition of Atherosclerotic
Plaque Progression in apoE /  Mice at
High HDL Doses is Associated with
Down-Regulation of ABCA1
The HDL mimetic, CER-001, as well as purified HDL, induce
down-regulation of ABCA1 in a dose-dependent manner. This
observation needs to be considered in the context of previous
observations. Historically, ABCA1 in macrophages was observed
to be down-regulated in vitro by incubationwithHDL (Langmann
et al., 1999). In vivo, a scrutiny analysis of the first randomized trial
of HDL infusion in humans using an apoA-IMilano/phospholipid
complex has shown a trend for less efficacy at the higher dose of
45 mg/kg than at the lower dose of 15 mg/kg (Nissen et al., 2003).
A similar observation was made during the CER-001 clinical trial
(CHI-SQUARE) where a promising effect on plaque regression
was detected only at the lowest dose of 3mg/kg (Tardif et al., 2014),
with an attenuation of effect at the higher doses.
We examined the CER-001 and HDL3 dose response in vivo by
assessing plaque formation in ligatured carotid of apoE /  mice
fed a HCD. The left carotid of apoE /  mice was ligatured, and
groups of mice were subsequently fed with a HCD and treated
(retro-orbital injection) every second day with different doses of
CER-001 orHDL3 for twoweeks. After eight infusions, a gradually
Frontiers in Pharmacology | www.frontiersin.org October 2015 | Volume 6 | Article 2205
Barbaras CER-001, a pre-beta HDL mimetic
FIGURE 3 | Increase in plasma total (A), unesterified (B), and esterified
(C) cholesterol levels following infusion of CER-001. CER-001 was
infused into fasted rabbits at doses of: 0 (squares), 2.5 (triangles), 5 (inverted
triangles), 10 (diamonds) or 20 (circles) mg/kg. There were three animals per
group. At various times post dose, plasma total, unesterified and esterified
cholesterol levels were measured. Baseline values were subtracted to
determine the increase in cholesterol levels. The baseline values ranged from
0.41 to 1.08 g/l for total cholesterol, from 0.13 to 0.3 g/l for unesterified
cholesterol, and from 0.28 to 0.78 g/l for esterified cholesterol. By 30–34 h
post dose the values had returned to a value at or below baseline.
greater decrease of unesterified and total cholesterol content in
ligatured carotids was observed as the dose of CER-001 or HDL3
increased from 2 to 5 to 10 mg/kg. No decrease in cholesterol
content was observed for dose levels >10 mg/kg; the level of
cholesterol content above this dose was the same as that observed
in untreatedmice (Tardy et al., 2015). TheABCA1 protein content
in the ligatured carotids inversely followed that of cholesterol
content in a similar dose-relatedmanner. At doses at which plaque
formation in carotid was maximally inhibited (5 mg/kg of CER-
001 and HDL3), carotid artery ABCA1 protein levels were similar
to those of untreated animals. In contrast, at the 50 mg/kg dose
of CER-001 or HDL3, the carotid cholesterol content of plaque
burden was similar to that of untreated animals, and the carotid
artery ABCA1 protein level was decreased by half compared with
untreated animals. Thus, down-regulation ofmacrophageABCA1
induced by elevated concentrations of CER-001 or HDL3 appears
to attenuate the efficacy of the infused HDL to inhibit plaque
formation in the apoE /  mice ligatured carotid model; however,
at lower doses, increasing the dose of CER-001 and HDL3 up
to that observed threshold slowed progression of carotid plaque
while maintaining normal levels of ABCA1 expression.
As a Matter of Conclusion
ABCA1 mRNA and protein level are decreased after high dose
treatment with CER-001 or HDL3. Further analysis is required,
but one may hypothesize that the down-regulation of ABCA1
could occur when a low level of cholesterol is reached in the
macrophages. Another ABC transporter, ABCG1, also seems to
be involved in the cellular cholesterol efflux process mediated by
HDL particles. ABCG1 seems to act in addition to the action of
ABCA1 on cholesterol efflux with an appetency for larger HDL
particles than ABCA1 (Tarling, 2013). Unfortunately, in humans,
the real effect of ABCG1 on global cholesterol efflux and on
the development of the atherosclerotic plaque burden has not
been evaluated. Further study of a potential down-regulation of
ABCG1 by HDL, identical (or different) to ABCA1 could be very
informative for further understanding general cellular cholesterol
homeostasis.
We suggest that in order to have a full and efficient action
of HDL or HDL-mimetics on cholesterol efflux in macrophages,
we need to find the right dose to avoid down-regulation of
ABCA1, the “gate-keeper” of cholesterol efflux from the cell.
This would allow a continued cholesterol efflux toward the
HDL acceptors and consequently would facilitate a decrease in
atherosclerotic plaque burden. Further clinical trials with HDL
mimetics andCETP inhibitors, which increase theHDL-C plasma
concentration, need to take into account this phenomenon of
dose-dependent HDL-mediated down-regulation of ABCA1.
References
Ameli, S., Hultgardh-Nilsson, A., Cercek, B., Shah, P. K., Forrester, J. S.,
Ageland, H., et al. (1994). Recombinant apolipoprotein A-I Milano
reduces intimal thickening after balloon injury in hypercholesterolemic
rabbits. Circulation 90, 1935–1941. doi: 10.1161/01.CIR.90.4.
1935
Andrews, J., Kataoka, Y., Duong, M., Fendler, J., Nguyen, T., Puri, R., et al. (2014).
“Regression of coronary atherosclerosis in response to infusion of High-Density
lipoprotein-mimetic agent CER-001 in patients with acute coronary syndrome,”
in Proceedings of the 19th Annual Scientific Meeting of the International Society
of Cardiovascular Pharmacotherapy, Adelaide, SA.
Attie, A. D., Kastelein, J. P., and Hayden, M. R. (2001). Pivotal role of ABCA1
in reverse cholesterol transport influencing HDL levels and susceptibility to
atherosclerosis. J. Lipid Res. 42, 1717–1726.
Badimon, J. J., Badimon, L., and Fuster, V. (1990). Regression of atherosclerotic
lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.
J. Clin. Invest. 85, 1234–1241. doi: 10.1172/JCI114558
Badimon, J. J., Badimon, L., Galvez, A., Dische, R., and Fuster, V. (1989). High
density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed
rabbits. Lab. Invest. 60, 455–461.
Baron, R., Goffinet, M., Sy, G., Schwendeman, A., Keyserling, C., Barbaras, R., et al.
(2010). CER-001 a Novel HDL Mimetic: Characterization of In Vitro and In Vivo
Biological Activities. Chicago: American Heart Association. A. (Circulation).
Frontiers in Pharmacology | www.frontiersin.org October 2015 | Volume 6 | Article 2206
Barbaras CER-001, a pre-beta HDL mimetic
Bortnick, A. E. A., Rothblat, G. H. G. H., Stoudt, G., Hoppe, K. L., Royer, L. J.,
Mcneish, J., et al. (2000). The correlation of ATP-binding cassette 1mRNA levels
with cholesterol efflux from various cell lines. J. Biol. Chem. 275, 28634–28640.
doi: 10.1074/jbc.M003407200
Cogny, A., Atger, V., Paul, J. L., Soni, T., and Moatti, N. (1996). High-density
lipoprotein 3 physicochemicalmodifications induced by interactionwith human
polymorphonuclear leucocytes affect their ability to remove cholesterol from
cells. Biochem. J. 314(Pt 1), 285–292. doi: 10.1042/bj3140285
Feng, Y., Van Craeyveld, E., Jacobs, F., Lievens, J., Snoeys, J., and De Geest, B.
(2009). Wild-type apo A-I and apo A-IMilano gene transfer reduce native and
transplant arteriosclerosis to a similar extent. J. Mol. Med. 87, 287–297. doi:
10.1007/s00109-008-0427-y
Field, F. J., Watt, K., and Mathur, S. N. (2008). Origins of intestinal
ABCA1-mediated HDL-cholesterol. J. Lipid Res. 49, 2605–2619. doi:
10.1194/jlr.M800302-JLR200
Guasch, A., Deen, W. M., and Myers, B. D. (1993). Charge selectivity of the
glomerular filtration barrier in healthy and nephrotic humans. J. Clin. Invest.
92, 2274–2282. doi: 10.1172/JCI116831
Hirsh, B. J., Smilowitz, N. R., Rosenson, R. S., Fuster, V., and Sperling, L. S. (2015).
Utilization of and adherence to guideline-recommended lipid-lowering therapy
after acute coronary syndrome: opportunities for improvement. J. Am. Coll.
Cardiol. 66, 184–192. doi: 10.1016/j.jacc.2015.05.030
Hovingh, G. K., Smits, L. P., Stefanutti, C., Soran, H., Kwok, S., de Graaf, J.,
et al. (2015). The effect of an apolipoprotein A-I-containing high-density
lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness
in patients with homozygous familial hypercholesterolemia: the Modifying
OrphanDisease Evaluation (MODE) study.Am.Heart J. 169, 736–742 e731. doi:
10.1016/j.ahj.2015.01.008
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K.,
et al. (2011). Cholesterol efflux capacity, high-density lipoprotein function, and
atherosclerosis. N. Engl. J. Med. 364, 127–135. doi: 10.1056/NEJMoa1001689
Kootte, R. S., Smits, L. P., van der Valk, F. M., Dasseux, J. L., Keyserling, C. H.,
Barbaras, R., et al. (2015). Effect of open-label infusion of an apoA-I-containing
particle (CER-001) on RCT and artery wall thickness in patients with FHA. J.
Lipid Res. 56, 703–712. doi: 10.1194/jlr.M055665
Langmann, T., Klucken, J., Reil, M., Liebisch, G., Luciani, M. F., Chimini, G., et
al. (1999). Molecular cloning of the human ATP-binding cassette transporter
1 (hABC1): evidence for sterol-dependent regulation in macrophages.
Biochem. Biophys. Res. Commun. 257, 29–33. doi: 10.1006/bbrc.1999.
0406
Lewis, G. F., and Rader, D. J. (2005). New insights into the regulation of HDL
metabolism and reverse cholesterol transport. Circ. Res. 96, 1221–1232. doi:
10.1161/01.RES.0000170946.56981.5c
Mattjus, P., and Slotte, J. P. (1996). Does cholesterol discriminate between
sphingomyelin and phosphatidylcholine in mixed monolayers containing both
phospholipids? Chem. Phys. Lipids 81, 69–80. doi: 10.1016/0009-3084(96)
02535-2
Miyazaki, A., Sakuma, S., Morikawa, W., Takiue, T., Miake, F., Terano, T., et
al. (1995). Intravenous injection of rabbit apolipoprotein A-I inhibits the
progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb.
Vasc. Biol. 15, 1882–1888. doi: 10.1161/01.ATV.15.11.1882
Nanjee, M. N., Doran, J. E., Lerch, P. G., and Miller, N. E. (1999). Acute
effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma
lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 19, 979–989. doi:
10.1161/01.ATV.19.4.979
Nieuwdorp, M., Vergeer, M., Bisoendial, R. J., op ’t Roodt, J., Levels, H., Birjmohun,
R. S., et al. (2008). Reconstituted HDL infusion restores endothelial function
in patients with type 2 diabetes mellitus. Diabetologia 51, 1081–1084. doi:
10.1007/s00125-008-0975-2
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., et
al. (2003). Effect of recombinant ApoA-I Milano on coronary atherosclerosis in
patients with acute coronary syndromes: a randomized controlled trial. JAMA
290, 2292–2300. doi: 10.1001/jama.290.17.2292
Oram, J. F., Lawn, R. M., Garvin, M. R., and Wade, D. P. (2000). ABCA1
is the cAMP-inducible apolipoprotein receptor that mediates cholesterol
secretion from macrophages. J. Biol. Chem. 275, 34508–34511. doi:
10.1074/jbc.M006738200
Piccolo, R., Giustino, G., Mehran, R., and Windecker, S. (2015). Stable coronary
artery disease: revascularisation and invasive strategies. Lancet 386, 702–713.
doi: 10.1016/S0140-6736(15)61220-X
Ramstedt, B., and Slotte, J. P. (1999). Interaction of cholesterol with sphingomyelins
and acyl-chain-matched phosphatidylcholines: a comparative study of the effect
of the chain length.Biophys. J. 76, 908–915. doi: 10.1016/S0006-3495(99)77254-1
Rigotti, A., Acton, S. L., and Krieger, M. (1995). The class B scavenger receptors
SR-BI and CD36 are receptors for anionic phospholipids. J. Biol. Chem. 270,
16221–16224. doi: 10.1074/jbc.270.27.16221
Ross, R. (1999). Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 340,
115–126. doi: 10.1056/NEJM199901143400207
Shaw, J. A., Bobik, A., Murphy, A., Kanellakis, P., Blombery, P., Mukhamedova,
N., et al. (2008). Infusion of reconstituted high-density lipoprotein leads to
acute changes in human atherosclerotic plaque. Circ. Res. 103, 1084–1091. doi:
10.1161/CIRCRESAHA.108.182063
Suc, I., Brunet, S., Mitchell, G., Rivard, G. E., and Levy, E. (2003). Oxidative
tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse
J774 macrophages: role of scavenger receptors, classes A and B. J. Cell Sci. 116,
89–99. doi: 10.1242/jcs.00126
Tardif, J. C., Ballantyne, C. M., Barter, P., Dasseux, J. L., Fayad, Z. A., Guertin, M.
C., et al. (2014). Effects of the high-density lipoprotein mimetic agent CER-
001 on coronary atherosclerosis in patients with acute coronary syndromes: a
randomized trial. Eur. Heart J. 35, 3277–3288. doi: 10.1093/eurheartj/ehu171
Tardif, J.-C., Grégoire, J., L’Allier, P. L., Ibrahim, R., Lespérance, J., Heinonen, T.
M., et al. (2007). Effects of reconstituted high-density lipoprotein infusions on
coronary atherosclerosis: a randomized controlled trial. JAMA 297, 1675–1682.
doi: 10.1001/jama.297.15.jpc70004
Tardy, C., Goffinet, M., Boubekeur, N., Ackermann, R., Sy, G., Bluteau, A., et al.
(2014). CER-001, a HDL-mimetic, stimulates the reverse lipid transport and
atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient
mice. Atherosclerosis 232, 110–118. doi: 10.1016/j.atherosclerosis.2013.10.018
Tardy, C., Goffinet, M., Boubekeur, N., Cholez, G., Ackermann, R., Sy, G., et al.
(2015). HDL and CER-001 Inverse-dose dependent inhibition of atherosclerotic
plaque formation in apoE / mice: evidence of ABCA1 down-regulation.PLOS
ONE 10:e0137584. doi: 10.1371/journal.pone.0137584
Tarling, E. J. (2013). Expanding roles of ABCG1 and sterol transport. Curr. Opin.
Lipidol. 24, 138–146. doi: 10.1097/MOL.0b013e32835da122
van Leuven, S. I., Birjmohun, R. S., Franssen, R., Bisoendial, R. J., de Kort, H.,
Levels, J. H., et al. (2009). ApoAI-phosphatidylcholine infusion neutralizes the
atherothrombotic effects of C-reactive protein in humans. J. Thromb. Haemost.
7, 347–354. doi: 10.1111/j.1538-7836.2008.03175.x
Conflict of Interest Statement: The author declares that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Barbaras. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordancewith
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org October 2015 | Volume 6 | Article 2207
